PARIS--(BUSINESS WIRE)--Cellectis (Paris:ALCLS) and Genoway indicate that the sublicense agreement dated September 7, 2001, relating to the patents and patent applications belonging to the pool WO90/11354 has been terminated as of December 30, 2008. Cellectis and Genoway have agreed on the consequences of such termination of the sublicense agreement, allowing Genoway to deliver the orders placed after the termination and before November 12, 2009. A visa of Cellectis will be attached to the delivery of such orders. Cellectis and Genoway have therefore amicably and definitely closed their disagreement. About Cellectis S.A. Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools, meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors. To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending. Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code : ALCLS) in Paris and has secured over €70 million in funding since inception.
